ATE557038T1 - Herstellung von rekombinantem il-18 bindendem protein - Google Patents

Herstellung von rekombinantem il-18 bindendem protein

Info

Publication number
ATE557038T1
ATE557038T1 AT10184728T AT10184728T ATE557038T1 AT E557038 T1 ATE557038 T1 AT E557038T1 AT 10184728 T AT10184728 T AT 10184728T AT 10184728 T AT10184728 T AT 10184728T AT E557038 T1 ATE557038 T1 AT E557038T1
Authority
AT
Austria
Prior art keywords
binding protein
recombinant
preparation
composition
production
Prior art date
Application number
AT10184728T
Other languages
English (en)
Inventor
Urs Wieber
Thierry Ziegler
Original Assignee
Ares Trading Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ares Trading Sa filed Critical Ares Trading Sa
Application granted granted Critical
Publication of ATE557038T1 publication Critical patent/ATE557038T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
AT10184728T 2005-06-03 2006-06-01 Herstellung von rekombinantem il-18 bindendem protein ATE557038T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US68763105P 2005-06-03 2005-06-03
EP05104878 2005-06-03
EP05106429 2005-07-13

Publications (1)

Publication Number Publication Date
ATE557038T1 true ATE557038T1 (de) 2012-05-15

Family

ID=44352415

Family Applications (2)

Application Number Title Priority Date Filing Date
AT10184728T ATE557038T1 (de) 2005-06-03 2006-06-01 Herstellung von rekombinantem il-18 bindendem protein
AT06763472T ATE517917T1 (de) 2005-06-03 2006-06-01 Herstellung eines rekombinanten il-18-bindenden proteins

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT06763472T ATE517917T1 (de) 2005-06-03 2006-06-01 Herstellung eines rekombinanten il-18-bindenden proteins

Country Status (15)

Country Link
US (2) US7691611B2 (de)
EP (2) EP2267024B1 (de)
JP (2) JP5199073B2 (de)
AT (2) ATE557038T1 (de)
AU (1) AU2006254103B2 (de)
CA (1) CA2609060C (de)
CY (2) CY1111969T1 (de)
DK (2) DK2267024T3 (de)
ES (2) ES2385639T3 (de)
IL (1) IL187838A (de)
NO (1) NO342802B1 (de)
PL (2) PL1885753T3 (de)
PT (2) PT1885753E (de)
SI (2) SI2267024T1 (de)
WO (1) WO2006128908A1 (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK12942002A3 (sk) * 2000-02-10 2003-05-02 Abbott Laboratories Protilátky viažuce ľudský interleukín-18, spôsoby ich výroby a použitia
ATE399872T1 (de) 2003-03-11 2008-07-15 Serono Lab Expressionvektoren, die den promotor des ie2-gens des maus cytomegalovirus enthalten
AU2004238524B2 (en) * 2003-05-13 2011-06-23 Merck Serono Sa Active variants of the IL-18 binding protein and medical uses thereof
CA2541523A1 (en) 2003-10-21 2005-05-06 Applied Research Systems Ars Holding N.V. Minimal dna sequence acting as a chromatin insulator and its use in protein expression
ES2285543T3 (es) * 2003-11-05 2007-11-16 Ares Trading S.A. Procedimiento para la purificacion de la proteina de union a il-18.
US7968684B2 (en) 2003-11-12 2011-06-28 Abbott Laboratories IL-18 binding proteins
ATE375385T1 (de) 2004-03-01 2007-10-15 Ares Trading Sa Verwendung eines serumfreien zellkulturmediums zur produktion von il-18bp in säugerzellen
ES2313367T3 (es) 2004-06-29 2009-03-01 Ares Trading S.A. Procedimiento para la purificacion de proteina de union al il-18.
PT1891088E (pt) 2005-06-10 2011-12-19 Ares Trading Sa Processo para a purificação da proteína de ligação il-18
US20160145589A1 (en) 2011-06-24 2016-05-26 Green Cross Corporation Composition and formulation comprising recombinant human iduronate-2-sulfatase and preparation method thereof
SI2726600T1 (sl) * 2011-07-01 2017-07-31 Amgen Inc. Sesalska celična kultura
US9150841B2 (en) 2012-06-29 2015-10-06 Shire Human Genetic Therapies, Inc. Cells for producing recombinant iduronate-2-sulfatase
US20140004097A1 (en) * 2012-06-29 2014-01-02 Shire Human Genetic Therapies, Inc. Method of producing recombinant iduronate-2-sulfatase
KR101380740B1 (ko) 2012-06-29 2014-04-11 쉐어 휴먼 제네텍 세러피스, 인코포레이티드 이듀로네이트-2-설파타제의 정제
US8956830B2 (en) 2013-03-14 2015-02-17 Momenta Pharmaceuticals, Inc. Methods of cell culture
US9217168B2 (en) 2013-03-14 2015-12-22 Momenta Pharmaceuticals, Inc. Methods of cell culture
US9677105B2 (en) * 2013-03-14 2017-06-13 Momenta Pharmaceuticals, Inc. Methods of cell culture
SG10201802023RA (en) 2013-03-26 2018-05-30 Coherus Biosciences Inc Protein production method
WO2015032932A1 (en) 2013-09-05 2015-03-12 Ab2 Bio Sa Il-18 binding protein (il-18bp) in inflammatory diseases
USD759075S1 (en) * 2014-04-11 2016-06-14 Nutonian, Inc. Display screen with graphical user interface
USD759076S1 (en) * 2014-04-18 2016-06-14 Nutonian, Inc. Display screen with graphical user interface
CN107660150B (zh) 2015-03-05 2023-10-24 Ab2生物股份有限公司 Il-18结合蛋白(il-18bp)和抗体在炎性疾病中
KR101789509B1 (ko) * 2015-11-05 2017-10-26 주식회사 프로젠 재조합 인간 갑상선 자극 호르몬을 포함하는 조성물 및 상기 재조합 인간 갑상선 자극 호르몬의 생산 방법
HUE058924T2 (hu) 2017-10-16 2022-09-28 Regeneron Pharma Perfúziós eljárások
IL307155B2 (en) 2018-05-01 2025-11-01 Amgen Inc Antibodies with modulated glycan profiles
BR112022020256A2 (pt) 2020-04-09 2023-01-03 Aprilbio Co Ltd “anticorpo monoclonal ou um fragmento de ligação ao antígeno do mesmo, ácido nucleico, vetor de expressão, célula, composição, uso da composição e uso do anticorpo monoclonal ou fragmento de ligação ao antígeno do mesmo

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4588585A (en) 1982-10-19 1986-05-13 Cetus Corporation Human recombinant cysteine depleted interferon-β muteins
US4737462A (en) 1982-10-19 1988-04-12 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β
US4959314A (en) 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins
US5116943A (en) 1985-01-18 1992-05-26 Cetus Corporation Oxidation-resistant muteins of Il-2 and other protein
US5266476A (en) 1985-06-18 1993-11-30 Yeda Research & Development Co., Ltd. Fibrous matrix for in vitro cell cultivation
US5017691A (en) 1986-07-03 1991-05-21 Schering Corporation Mammalian interleukin-4
US4879111A (en) 1986-04-17 1989-11-07 Cetus Corporation Treatment of infections with lymphokines
US4965195A (en) 1987-10-26 1990-10-23 Immunex Corp. Interleukin-7
US4904584A (en) 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
GEP20002142B (en) 1991-01-18 2000-06-25 Amgen Inc Method for Treatment and Prevention of TNF Mediated Diseases
JP4306813B2 (ja) * 1995-09-19 2009-08-05 アスビオファーマ株式会社 動物細胞の新規培養方法
AU706504B2 (en) 1996-02-20 1999-06-17 Merck Serono Sa Hybrid proteins which form heterodimers
ATE486937T1 (de) 1996-07-12 2010-11-15 Genentech Inc Chimärische heteromultimerische adhesine
IL121860A0 (en) 1997-08-14 1998-02-22 Yeda Res & Dev Interleukin-18 binding proteins their preparation and use
CA2377513A1 (en) 1999-06-25 2001-01-04 Universitat Zurich Hetero-associating coiled-coil peptides
ATE407697T1 (de) 1999-07-13 2008-09-15 Bolder Biotechnology Inc Erythropoietin immunglobulin fusionsproteine
IL131047A0 (en) 1999-07-22 2001-01-28 Yeda Res & Dev Use of il-18 inhibitors
UA74557C2 (en) * 1999-09-03 2006-01-16 Applied Research Systems A method for producing a heterologous secreted protein from chinese hamster ovaries cells grown on microcarriers
RS51737B (sr) 2000-02-21 2011-10-31 Laboratoires Serono Sa. Korišćenje inhibitora il-18
CA2407895C (en) 2000-05-05 2012-12-18 Applied Research Systems Ars Holding N.V. Use of il-18 inhibitors for the treatment and/or prevention of atherosclerosis
IL140110A0 (en) * 2000-12-05 2002-02-10 Applied Research Systems Improvement of homogeneity and secretion of recombinant proteins in mammalian systems
IL157024A0 (en) 2001-01-29 2004-02-08 Applied Research Systems Il-18 inhibitors in heart disease
JP2004530432A (ja) 2001-03-08 2004-10-07 アレス・トレーディング・ソシエテ・アノニム インターロイキン−１８変異体、その産生および使用
BR0210904A (pt) 2001-05-16 2005-08-16 Yeda Res & Dev Uso de inibidores de il-18 para o tratamento ou prevenção de sepse
US7655616B2 (en) 2001-05-25 2010-02-02 Ares Trading S.A. Use of IL-18 inhibitors for treating head injuries
UA78516C2 (en) 2001-08-10 2007-04-10 Applied Research Systems Use of inhibitors of il-18 for treatment and/or prevention of hypersensitivity disorders, and in particular of delayed-type hypersensitivity
US9592267B2 (en) 2002-03-22 2017-03-14 Merck Serono Sa Use of IL-18BP for treatment of peripheral vascular diseases
EP1529109A2 (de) 2002-08-14 2005-05-11 Avidis SA Herstellung von multimeren proteinen unter verwendung eines c4bp-gerüstes
US20050009149A1 (en) 2002-10-11 2005-01-13 West James W. Production of homotrimeric fusion proteins
EP1575998A4 (de) * 2002-12-23 2007-07-25 Bristol Myers Squibb Co Verfahren zur kultivierung vonsäugetierzellen zur proteinproduktion
ATE399872T1 (de) 2003-03-11 2008-07-15 Serono Lab Expressionvektoren, die den promotor des ie2-gens des maus cytomegalovirus enthalten
AU2004238524B2 (en) 2003-05-13 2011-06-23 Merck Serono Sa Active variants of the IL-18 binding protein and medical uses thereof
CA2541523A1 (en) 2003-10-21 2005-05-06 Applied Research Systems Ars Holding N.V. Minimal dna sequence acting as a chromatin insulator and its use in protein expression
ES2285543T3 (es) * 2003-11-05 2007-11-16 Ares Trading S.A. Procedimiento para la purificacion de la proteina de union a il-18.
ATE375385T1 (de) 2004-03-01 2007-10-15 Ares Trading Sa Verwendung eines serumfreien zellkulturmediums zur produktion von il-18bp in säugerzellen
ES2313367T3 (es) * 2004-06-29 2009-03-01 Ares Trading S.A. Procedimiento para la purificacion de proteina de union al il-18.
PT1891088E (pt) 2005-06-10 2011-12-19 Ares Trading Sa Processo para a purificação da proteína de ligação il-18

Also Published As

Publication number Publication date
US7691611B2 (en) 2010-04-06
DK2267024T3 (da) 2012-06-25
WO2006128908A1 (en) 2006-12-07
EP1885753A1 (de) 2008-02-13
PT1885753E (pt) 2011-10-06
SI1885753T1 (sl) 2011-12-30
EP1885753B1 (de) 2011-07-27
SI2267024T1 (sl) 2012-09-28
JP5199073B2 (ja) 2013-05-15
IL187838A (en) 2011-07-31
CY1111969T1 (el) 2015-11-04
PL1885753T3 (pl) 2011-12-30
PL2267024T3 (pl) 2012-10-31
ES2385639T3 (es) 2012-07-27
ES2370417T3 (es) 2011-12-15
JP2008541748A (ja) 2008-11-27
US20080199913A1 (en) 2008-08-21
IL187838A0 (en) 2008-03-20
CY1113056T1 (el) 2016-04-13
CA2609060A1 (en) 2006-12-07
US20100137195A1 (en) 2010-06-03
EP2267024B1 (de) 2012-05-09
ATE517917T1 (de) 2011-08-15
PT2267024E (pt) 2012-06-01
NO342802B1 (no) 2018-08-06
AU2006254103A1 (en) 2006-12-07
DK1885753T3 (da) 2011-10-03
JP2013048633A (ja) 2013-03-14
EP2267024A1 (de) 2010-12-29
CA2609060C (en) 2014-07-15
AU2006254103B2 (en) 2012-09-06
JP5837476B2 (ja) 2015-12-24
NO20076672L (no) 2008-02-22

Similar Documents

Publication Publication Date Title
CY1113056T1 (el) Παρασκευη ανασυνδυασμενης συνδετικης πρωτεϊνης il-18
SG155183A1 (en) Process for the preparation of glycosylated interferon beta
DE602007011171D1 (de) Zusammensetzung und Verfahren zur Herstellung von Steviolglykosiden
SE0301010D0 (sv) Novel compounds
EA200700255A1 (ru) Новый карбамилированный еро и способ его получения
WO2006029094A3 (en) Erythropoietin derivatives with altered immunogenicity
SE0301009D0 (sv) Novel compounds
DE602006010132D1 (de) Zwischenprodukte für die Herstellung von Trans-5-Chlor-2-Methyl-2,3,3a,12b-Tetrahydro-1h-DibenzÄ2,3:6,7ÜOxepinoÄ4,5-cÜPyrrol
TW200745003A (en) Novel compounds
ATE501114T1 (de) Herstellung von 3-pentennitril aus 1,3-butadien
DK1930439T3 (da) Neurotrofe faktorer
WO2007052023A3 (en) Novel compounds
TW200740841A (en) Polypeptides having antimicrobial activity and polynucleotides encoding same
IL191968A0 (en) Recombinant production of heparin binding proteins
PT1969127E (pt) Processo de produção de proteínas dependentes da vitamina k biologicamente activos por métodos recombinantes
NO20082989L (no) Fremstiling av gamma-aminosyrer som har affinitet for alfa-2-deltaproteinet
TW200745159A (en) IL-6 binding proteins
WO2004039834A3 (en) Recombinant protein variants
ATE496913T1 (de) Neue, langwirksame betamimetika zur behandlung von atemwegserkrankungen
DE602004002692D1 (de) Verfahren zur Herstellung von Topiramate
DE602006009439D1 (de) Wanderbettverfahrenverfahren zur Herstellung von Phenylalkanen
ATE454401T1 (de) Il-18bp promoter herstellung und verwendung
ATE540961T1 (de) Furanosederivate fuer die herstellung von atorvastatin
DK1988086T3 (da) Fremgangsmåde til opløsning af citalopram via dets (S)-berigede citalopramtartratforbindelse
DK1935981T3 (da) Fremgangsmåde til fremstilling af rekombinant protein